Full notification fileGeneral informationNotification NumberB/NL/13/002Member State to which the notification was sentNetherlandsDate of acknowledgement from the Member State Competent Authority09/01/2013Title of the ProjectIntradermal vaccination with naked DNA, TTFC-E7SH, encoding the fusion protein domain1 of tetanus toxin fragment C and the shuffled version of the Human papilloma virus (HPV) E7 oncoprotein for the induction of E7 specific T cell immunity in stage IV squamous cell cancer patientsProposed period of release:09/04/2013 to 09/04/2023Name of the Institute(s) or Company(ies)Stichting Het Nederlands Kanker Instituut, Plesmanlaan 121
1066 CX Amsterdam
PO Box 90203
1006 BE Amsterdam;
3. Is the same GMO release planned elsewhere in the Community?Not knownHas the same GMO been notified elsewhere by the same notifier?NoGMO characterizationGMO is a:Other: no taxonomic classification.Identity of the GMO:The medicinal product is not a GMO per se. It is an investigational gene therapy medicinal product consisting of a purified plasmid DNA (pDNA) drug substance.
The plasmid DNA does not have a taxonomic classification.Information relating to the recipient or parental organisms from wich the GMO is derived
European Commission administrative informationConsent given by the Member State Competent Authority:Not known